Literature DB >> 16275189

Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting.

Antonio Micari1, Todd A Belcik, Eduardo A Balcells, Eric Powers, Kevin Wei, Sanjiv Kaul, Jonathan R Lindner.   

Abstract

The aim of this study was to use myocardial contrast echocardiography to evaluate the effect of intravenous adenosine on microvascular reflow in patients with acute myocardial infarction who underwent primary coronary stenting (PCS). Thirty patients who underwent primary PCS for acute myocardial infarction were randomized to intravenous adenosine (50 to 70 mug/kg/min) or vehicle for 3 hours. Myocardial contrast echocardiography was performed before and sequentially after PCS to determine the risk area during coronary occlusion and infarct size. The risk area was similar in the adenosine- and placebo-treated patients. The infarct size as a ratio to the risk area was smaller in patients treated with adenosine when measured at 3 to 5 days (0.37 +/- 0.29 vs 0.68 +/- 0.25, p <0.01) and at 4 weeks (0.34 +/- 0.26 vs 0.60 +/- 0.21, p <0.01) after PCS. This effect was greatest when patency was achieved <4 hours after symptom onset (0.18 +/- 0.18 vs 0.74 +/- 0.31, p <0.05), with little effect after 4 hours. The relative microvascular blood volume in the risk area at 4 weeks was higher in patients receiving adenosine than in those receiving placebo (0.73 +/- 0.22 vs 0.57 +/- 0.20, p <0.01), and was highest when patency was achieved in <4 hours. In conclusion, the adjunctive use of intravenous adenosine after PCS reduces the infarct size relative to the risk area. This beneficial effect occurs primarily in those undergoing early intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275189     DOI: 10.1016/j.amjcard.2005.06.090

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Authors:  S A Harding
Journal:  Heart       Date:  2006-04-10       Impact factor: 5.994

Review 2.  The management of thrombotic lesions in the cardiac catheterization laboratory.

Authors:  Fadi Matar; Jad Mroue
Journal:  J Cardiovasc Transl Res       Date:  2011-10-21       Impact factor: 4.132

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 4.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

5.  T2-weighted imaging to assess post-infarct myocardium at risk.

Authors:  Matthias G Friedrich; Han W Kim; Raymond J Kim
Journal:  JACC Cardiovasc Imaging       Date:  2011-09

6.  Timing of adenosine 2A receptor stimulation relative to reperfusion has differential effects on infarct size and cardiac function as assessed in mice by MRI.

Authors:  Zequan Yang; Joel Linden; Stuart S Berr; Irving L Kron; George A Beller; Brent A French
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-10       Impact factor: 4.733

7.  The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Khalill Ramjane; Lei Han; Chang Jin
Journal:  Exp Clin Cardiol       Date:  2008

8.  Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist.

Authors:  Rajan A G Patel; David K Glover; Alexis Broisat; Hasan K Kabul; Mirta Ruiz; N Craig Goodman; Christopher M Kramer; Denis J Meerdink; Joel Linden; George A Beller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-05       Impact factor: 4.733

Review 9.  Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and management.

Authors:  Sabine Vecchio; Elisabetta Varani; Tania Chechi; Marco Balducelli; Giuseppe Vecchi; Matteo Aquilina; Giulia Ricci Lucchi; Alessandro Dal Monte; Massimo Margheri
Journal:  World J Cardiol       Date:  2014-06-26

10.  Efficacy of combination treatment with intracoronary abciximab and aspiration thrombectomy on myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary coronary stenting.

Authors:  Sung Gyun Ahn; Seung-Hwan Lee; Ji Hyun Lee; Jun-Won Lee; Young Jin Youn; Min-Soo Ahn; Jang-Young Kim; Byung-Su Yoo; Junghan Yoon; Kyung-Hoon Choe; Seung-Jea Tahk
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.